The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer Thoracic Oncology

Conclusion Despite improved progression-free survival on therapy that did not contain erlotinib for KRAS mut+ patients and improved prognosis for mesenchymal tumors, better biomarker-driven treatment strategies are still needed.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Translational Oncology, Chemotherapy, Lung Thoracic Oncology Source Type: research

Related Links:

.
Source: International Journal of Sexual Health - Category: Sexual Medicine Authors: Source Type: research
.
Source: American Journal of Sexuality Education - Category: Sexual Medicine Authors: Source Type: research
.
Source: Systems Biology in Reproductive Medicine - Category: Sexual Medicine Authors: Source Type: research
.
Source: Systems Biology in Reproductive Medicine - Category: Sexual Medicine Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
.
Source: British Journal of Neurosurgery - Category: Neurosurgery Authors: Source Type: research
More News: Cancer & Oncology